Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibody test tracks hepatitis C treatment:

This article was originally published in Clinica

Executive Summary

A reduction in levels of so-called envelope antibodies in chronic hepatitis C patients is a good indication of successful interferon treatment, according to research in the Journal of Medical Virology (February). Researchers from the University Hospital in Ghent, Belgium, explained that only a small proportion of patients have a sustained biochemical and virologic response to interferon-alpha therapy and in these, the decline of anti-E1 envelope antibodies is most pronounced. These antibodies, which are highly variable, are detected using recombinant proteins containing HCV 1b sequences in enzyme immunoassays, in order to improve the match between virus and antigen.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel